Peking University Cancer Hospital & Institute
bjcancer.orgLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
254
Active
110
Phase 3
11
Total enrollment
122,814
Pipeline matrix
Showing 40 of 111 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Traditional Chinese medicine (TCM) hand and foot baths | — | — | — | — | — | 1 | |
| Methylcobalamin | — | — | — | — | — | 1 | |
| Dose Escalation | — | — | — | — | — | 1 | |
| Camrelizumab | — | — | — | — | 5 | ||
| Sunitinib | — | — | — | — | 2 | ||
| Vorolanib Tablets+Everolimus | — | — | — | — | — | 1 | |
| Camrelizumab ＋Immunotherapy | — | — | — | — | — | 1 | |
| Afatinib + Toripalimab | — | — | — | — | — | 1 | |
| Dalpiciclib + Pyrotinib | — | — | — | — | — | 1 | |
| Camrelizumab + Apatinib | — | — | — | — | — | 1 | |
| camrelizumab+apatinib+TMZ | — | — | — | — | — | 1 | |
| camrelizumab+apatinib | — | — | — | — | — | 1 | |
| CapeOX | — | — | — | — | — | 1 | |
| Fruquintinib and Tislelizumab combined with mCapeOX | — | — | — | — | — | 1 | |
| Carboplatin | — | — | — | — | 4 | ||
| KN046 | — | — | — | — | — | 4 | |
| Bevacizumab | — | — | — | — | — | 5 | |
| Tislelizumab | — | — | — | — | 4 | ||
| Cisplatin | — | — | — | — | 3 | ||
| Pemetrexed | — | — | — | — | 2 | ||
| Iparomlimab/Tuvonralimab | — | — | — | — | — | 2 | |
| SHR-A1811 | — | — | — | — | — | 2 | |
| Oxaliplatin | — | — | — | 8 | |||
| Capecitabine | — | — | — | — | 7 | ||
| Regorafenib | — | — | — | — | 4 | ||
| Pyrotinib | — | — | — | — | 2 | ||
| Pertuzumab | — | — | — | — | 2 | ||
| Combination product: Trastuzumab + Pertuzumab | — | — | — | — | 2 | ||
| Apatinib | — | — | — | — | — | 4 | |
| apatinib mesylate | — | — | — | — | — | 3 | |
| CDK4/6 inhibitor | — | — | — | — | — | 2 | |
| Niraparib | — | — | — | — | 2 | ||
| Axitinib | — | — | — | — | 2 | ||
| Ensartinib | — | — | — | — | — | 2 | |
| Vebreltinib combined with Furmonertinib | — | — | — | — | — | 1 | |
| Adebrelimab (SHR-1316) + Nab-paclitaxel + Cisplatin | — | — | — | — | — | 1 | |
| Adebrelimab Induction Therapy Group | — | — | — | — | — | 1 | |
| Adebrelimab Maintenance Therapy Group | — | — | — | — | — | 1 | |
| Adebrelimab with concurrent chemoradiotherapy | — | — | — | — | — | 1 | |
| chidamide and golidocitinib | — | — | — | — | — | 1 |
71 more active programs hidden
Next readouts
- 2023-12-31
- 2024-03-01
- 2024-11-30
- 2024-12-01
- 2025-05-01
- 2025-06-30
- 2025-07-07
- 2025-12-20
- 2025-12-30
- 2025-12-31
Top conditions
- Melanoma18
- Breast Cancer13
- Rectal Cancer12
- Gastric Cancer9
- Colorectal Cancer8
- Solid Tumor8
- Neoplasm Metastasis6
- Breast Neoplasms6
Frequently asked questions about Peking University Cancer Hospital & Institute
- How many clinical trials does Peking University Cancer Hospital & Institute have on ClinicalTrials.gov?
- Peking University Cancer Hospital & Institute is listed as the lead sponsor on 254 clinical trials in ClinicalTrials.gov, 110 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Peking University Cancer Hospital & Institute's trials are in Phase 3?
- 11 of Peking University Cancer Hospital & Institute's trials are in Phase 3, spread across 111 active drug programs.
- What therapeutic areas does Peking University Cancer Hospital & Institute focus on?
- Peking University Cancer Hospital & Institute's most-studied conditions on ClinicalTrials.gov are Melanoma, Breast Cancer, Rectal Cancer, Gastric Cancer, Colorectal Cancer.
- When are Peking University Cancer Hospital & Institute's next clinical trial readouts?
- Peking University Cancer Hospital & Institute has 10 upcoming primary-completion readouts tracked here; the soonest is “Paclitaxel (Albumin-bound) Combined With Oxaliplatin and S-1 Conversion Therapy for Gastric Adenocarcinoma”, expected around 2023-12-31.